High Katherine A 4
4 · CRISPR Therapeutics AG · Filed May 31, 2024
Insider Transaction Report
Form 4
High Katherine A
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-05-30+13,000→ 13,000 totalExercise: $54.06Exp: 2034-05-30→ Common Shares (13,000 underlying)
Footnotes (1)
- [F1]This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders.